My point is it was a curious/abnormal series of events that led us to where we are now
And my point is that you are chasing gold at the end of the rainbow - of a generics company. And because its the generics business, every time it gets an approval, that means the door is open to OTHER approvals of the same brand, without warning not notice, regardless of whether they occur on the same day, the same year, or next year, etc. By now you understand what competition means in generics pricing, and that in reality the much sought-after "duopoly" amounts to an investment on the edge of a cliff.